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Background: Although the standard treatment of acute appendicitis (AA) consists of an early appendectomy, there
has recently been both an interest and an increase in the use of antibiotic therapy as the primary treatment for
uncomplicated AA. However, the use of antibiotic therapy in the treatment of uncomplicated AA is still
controversial.
Methods/design: The APPAC trial is a randomized prospective controlled, open label, non-inferiority multicenter
trial designed to compare antibiotic therapy (ertapenem) with emergency appendectomy in the treatment of
uncomplicated AA. The primary endpoint of the study is the success of the randomized treatment. In the antibiotic
treatment arm successful treatment is defined as being discharged from the hospital without the need for surgical
intervention and no recurrent appendicitis during a minimum follow-up of one-year (treatment efficacy). Treatment
efficacy in the operative treatment arm is defined as successful appendectomy evaluated to be 100%. Secondary
endpoints are post-intervention complications, overall morbidity and mortality, the length of hospital stay and sick
leave, treatment costs and pain scores (VAS, visual analoque scale). A maximum of 610 adult patients (aged 18–60
years) with a CT scan confirmed uncomplicated AA will be enrolled from six hospitals and randomized by a closed
envelope method in a 1:1 ratio either to undergo emergency appendectomy or to receive ertapenem (1 g per day)
for three days continued by oral levofloxacin (500 mg per day) plus metronidazole (1.5 g per day) for seven days.
Follow-up by a telephone interview will be at 1 week, 2 months and 1, 3, 5 and 10 years; the primary and
secondary endpoints of the trial will be evaluated at each time point.
Discussion: The APPAC trial aims to provide level I evidence to support the hypothesis that approximately 75–85%
of patients with uncomplicated AA can be treated with effective antibiotic therapy avoiding unnecessary
appendectomies and the related operative morbidity, also resulting in major cost savings.
Trial registration: Clinicaltrials.gov NCT01022567
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Emergency appendectomy for acute appendicitis (AA) is
an effective and universally accepted procedure performed
more than 300,000 times annually in the United States [1].
The life-time risk to have AA is 8.6% in men and 6.7% in
women; the risk for emergency appendectomy is 12% and
23%, respectively [2]. In Finland, approximately 6,500 ap-
pendectomies are performed annually with a mean hos-
pital stay of 2.7 days [3]. For over a century it has been
generally believed that AA progresses invariably from early
inflammation to later gangrene and perforation, and that
emergency appendectomy is always required for surgical
source control [4].
Although non-operative management with antibiotics
of uncomplicated acute diverticulitis and salpingitis has
been well established, the non-operative management of
AA remains controversial. There is one Cochrane analysis
[5], five meta-analysis [6-10] and some reviews [11,12] of
non-operative treatment of AA. Although a non-surgical
approach in AA may reduce the complication rate, the
lower efficacy may prevent antibiotic therapy from being a
first-hand alternative to surgery [8]. On the other hand,
appendectomy may not be always necessary for the
patients with uncomplicated AA, as many patients resolve
spontaneously and others may be treated with antibiotic
therapy [13-17]. Six randomized controlled trials (RCTs)
have compared the efficacy of antibiotic therapy with sur-
gery in the treatment of AA [13-18].
Abdominal computed tomography (CT) is the best
non-invasive diagnostic tool available and it has become
more commonly used in this respect for patients with
AA with a high sensitivity and specificity [19,20]. Most
previous RCTs comparing antibiotic therapy with sur-
gery in the management of AA are lacking abdominal
CT to confirm AA [13-16]. Therefore, a well-designed
controlled trial comparing non-operative management
versus early appendectomy for uncomplicated AA
corroborated by CT imaging has been called for [8]. CT
scan is used in the APPAC trial for research purposes as
CT scan confirmed uncomplicated acute appendicitis will
prevent bias in our result as the antibiotic group patients
are also treated for acute appendicitis enabling accurate
comparison with the surgery group. The only previous
study of antibiotic treatment in CT scan diagnosed AA
indicated that amoxicillin/clavulanic acid was not non-
inferior to emergency appendectomy in the treatment of
AA, but identification of predictive markers, such as
appendicolith, on CT scans might enable improved
targeting of antibiotic treatment [17]. CT scanning of
patients with suspected AA has been considered essential
to exclude non-appendicitis and to identify perforated ap-
pendicitis or an appendiceal abscess reducing the number
of non-therapeutic appendectomies and overall admission
costs [19-22]. Meta-analysis and review articles suggestthat although antibiotics may be used as the primary treat-
ment for selected patients with suspected uncomplicated
AA, this is unlikely to supersede appendectomy at present
[6-10]. The recent meta-analysis by Mason et al. [8] identi-
fied non-operative management of uncomplicated AA to
be associated with significantly fewer complications, better
pain control and shorter sick leave, but overall having
inferior efficacy because of high rate of recurrence
(10 – 20%) in comparison with appendectomy.
Objective
The objective of the APPAC trial is to compare antibiotic
therapy (ertapenem) with emergency appendectomy in the
treatment of CT scan confirmed uncomplicated AA. The
overall objective of the study is to provide level I evidence
to support the hypothesis that approximately 75–85% of
patients with uncomplicated AA can be treated without
surgery by using effective antibiotic therapy.
The primary endpoint will be the success of the
randomized treatment. In the antibiotic treatment arm
successful treatment is defined as being discharged from
the hospital without the need for surgical intervention
and no recurrent appendicitis during a minimum follow-
up of one-year (treatment efficacy). Treatment efficacy
in the operative treatment arm is defined as success-
ful appendectomy evaluated to be 100%. Secondary
endpoints are post-intervention complications, overall
morbidity and mortality, the length of hospital stay and
sick leave, treatment costs and pain VAS-scores.
Methods/Design
Trial design
The APPAC trial has been designed as a prospective
randomized controlled, open label, non-inferiority
multicenter trial to compare antibiotic therapy (intraven-
ous ertapenem) with emergency appendectomy in the
treatment of uncomplicated appendicitis.
Participants
Patients presenting with suspected uncomplicated AA
will be enrolled from six participating Finnish hospitals;
three university hospitals and three central hospitals.
The university hospitals are Turku, Tampere and Oulu
University Hospitals, and the central hospitals are
Mikkeli, Jyväskylä and Seinäjoki Central Hospitals.
All adult patients (aged 18 – 60 years old) admitted to
the emergency department with a clinical suspicion of
uncomplicated AA will be studied carefully by attending
surgeons at the emergency departments of the partici-
pating hospitals. Clinical history, physical investigation
and laboratory blood tests (blood hemoglobin g/l and
leukocyte count E9/l, plasma C - reactive protein mg/l
and creatinine μmol/l and serum human chorionic go-
nadotropin U/l) as well as urine analysis are undertaken.
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gency ward, pain scores (VAS 0–10) will be recorded. If
clinical history and physical examination suggest that the
patient has uncomplicated AA, the patient is eligible for
inclusion in the APPAC study and the patients are
informed of the protocol and invited to participate. After
signed informed consent is obtained, a CT scan will be
performed to confirm the diagnosis of uncomplicated AA.
Inclusion criteria
▪ Signed informed consent
▪Age between 18 and 60 years
▪ CT scan diagnosis of uncomplicated AA
Exclusion criteria
▪ Age < 18 years or > 60 years
▪ Pregnancy or lactating
▪ Allergy to contrast media or iodine
▪ Renal insufficiency, serum creatinine > 150 μmol/l
▪ Metformine medication
▪ Peritonitis
▪ Inability to co-operate and give informed consent
▪ Serious systemic illness
▪ Complicated AA in a CT scan: Appendicolith,
perforation, periappendicular abscess or suspicion of a
tumourRegistration procedure
After signed informed consent, all patients evaluated for
study enrollment are registered in every participating in-
stitution using the same data collection sheet. The pa-
tient namecode, date of birth, sex, eligible criteria and
names of responsible physicians will be registered along
with the clinical information. The data collection sheets
will be combined into a common database at the main
research center Turku University Hospital.Randomization
After confirming the diagnosis of uncomplicated AA by
a CT scan, patients will be randomized by a closed enve-
lope method either to undergo appendectomy or to
receive antibiotic therapy with intravenous ertapenem.
The randomization is performed in 1:1 equal alloca-
tion ratio. The 610 opaque, sealed, and sequentially
numbered randomization envelopes are mixed and
distributed to research hospitals by the main research
center according to each hospital district population.
To randomize a patient, an independent surgeon
on duty will open the next consecutively numbered
envelope.Interventions
Surgical treatment
After randomization to undergo operative treatment,
open appendectomy will be performed by standard tech-
nique using a McBurney right lower quadrant muscle
splitting incision. Prophylactic antibiotic as a single dose
of 1.5 g cefuroxime and 500 mg metronidazole is
administered approximately 30 min preoperatively. The
histopathological examination of the appendix will be
performed and the histological diagnosis of acute appen-
dicitis requires involvement of the muscularis of the ap-
pendix (transmural neutophil invasion).
Antibiotic therapy
After randomization to receive antibiotic treatment,
intravenous ertapenem sodium 1 g per day will be
administered for three days with the first dose given in
the emergency room. The clinical status of the antibiotic
group patients will be re-evaluated within 12 – 24 hours
after admission and monitored during the whole stay. If
progressive infection, perforated appendicitis or periton-
itis is clinically suspected, the patient will undergo
emergency appendectomy and the histopathological
examination of the appendix will be performed. In case
of ertapenem allergy (known or newly diagnosed),
the intravenous antibiotic treatment will consist of
tazobactam 4 g × 3 combined with metronidazole
500 mg × 3. The three-day intravenous antibiotic
treatment will be followed by seven days of oral anti-
biotic therapy with levofloxacin 500 mg × 1 combined
with metronidatzole 500 mg × 3 resulting in ten-day
total duration of the antibiotic therapy. In case of allergy
for fluoroquinolones (known or newly diagnosed),
levofloxacin will be replaced either with cefalexin 500
mg × 3 or clindamycin 400 mg × 3.
Outcome parameters
The primary end-point
Success of the randomized treatment
The primary endpoint of treatment success in this
non-inferiority trial is defined in the antibiotic treatment
arm as the resolution of AA with antibiotic treatment
resulting in discharge from the hospital without the need
for surgical intervention and no recurrent appendicitis
during a minimum follow-up of one-year (treatment effi-
cacy). Treatment efficacy in the operative treatment arm




▪ Late recurrence of AA after conservative treatment
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▪ Treatment costs
▪ Post-intervention pain scores (VAS 0–10) and use of
pain medication
▪ Sick leave
A recurrent AA will be diagnosed on a clinical basis.
A patient with recurrent AA will always undergo ap-
pendectomy and the recurrent AA diagnosis will be
verified by surgery and histopathological examination of
removed appendix. For the primary study endpoint, the
overall treatment efficacy will favor surgical treatment.
For the secondary end-points, late recurrence of AA
after one-year follow-up is naturally associated only
with the antibiotic treatment arm. The outcome
regarding the other secondary endpoints of overall mor-
bidity, sick leave, treatment costs, pain scores and pain
medication utilization in the antibiotic treatment arm is
evaluated to be superior compared with surgical treat-
ment. The duration of the hospital stay will most likely
be similar in both treatment arms as the hospitalization
of antibiotic group patients is protocol-driven in the
trial design to ensure the safety of this unproved thera-
peutic modality.
Pre-intervention data
▪ Date of birth
▪ Sex
▪ Surgeon on duty
▪ Pain score (VAS) on admission
▪ Hemoglobin
▪ Leukocyte count
▪ CRP (C-reactive protein)
▪ Creatinine
▪ Human chorionic gonadotropin
▪ Urine analysis
▪ CT-scan data (see abdominal computed tomography)





▪ The timing of the operation and reasons for possible
operative delay
▪ Operative findings
▪ Possible peroperative perforation of the appendix
▪ Operating time
Antibiotic therapy
▪ The administered intravenous antibiotic▪ Clinical status within 12 – 24 hours after admission
and the surgeon performing the evaluation
▪ Possible cross-over to operative treatment and the
clinical symptoms necessitating emergency
appendectomy
▪ Adverse reactions to antibiotics
Post-intervention data
Surgical treatment
▪ Clinical wound infection (surgical site infection, SSI)
occurring within 30 days after the operative procedure
diagnosed by a surgeon or positive bacterial culture
○Superficial incisional SSI – infection involves only
skin and subcutaneous tissue of incision presenting
with at least one of the following signs or symptoms of
infection
▪ purulent drainage from the superficial incision
▪ pain or tenderness
▪ localized swelling
▪ redness or heat
○Deep incisional SSI – infection involves deep tissues,
such as fascial and muscle layers
▪ purulent drainage from the deep incision
▪ deep incision is deliberately opened by a surgeon in
case of fever and localized pain or the incision
spontaneously dehisces
○Organ/space SSI – infection involves any part of the
anatomy in organs and spaces other than the incision,
which was opened or manipulated during the operation
▪ Postoperative antibiotic treatment (at the hospital
and after discharge)
▪ Pain score (VAS) on discharge date
▪ Profession
▪ Sick leave
▪ Pain medication prescription
Follow-up
Patient outcome will be obtained during hospital stay
(days 0, 1, 2) and then by a phone interview at one week,
two months and at and one, three, five and ten years
after the intervention. At one week and two months pain
score (VAS), possible additional need for sick leave,
wound infections and recurrent AA will be registered.
At long-term follow-up of 1, 3, 5 and 10 years recurrent
AA and possible occurrence of appendiceal or cecal
tumors will be registered for the antibiotic therapy arm
and possible incisional hernias or other problems with
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adhesion related problems will be evaluated for both
study groups.
Abdominal computed tomography
All abdominal CT scans will be performed from the dia-
phragm to the pubic symphysis using multi-detector row
helical CT scanners (MDCT). A study series with con-
trast is performed during portovenous phase according
to standard imaging protocol. The radiation dose of CT
is set to be 6.7 mSv (range 5–7 mSv) depending on the
size of patient.
Normal appendix is 6 mm or less in diameter in < 60%
of patients [23]. The CT diagnosis of AA is based on the
diameter of the appendix exceeding 6 mm, thickening
and contrast enhancement of the appendiceal wall, in-
flammatory edema and minor fluid collection around
the appendix. A standardized radiology data sheet is
recorded for all patients undergoing a CT scan for a
suspected AA evaluated for participation in the trial. A
final CT diagnosis of uncomplicated AA requires a clear
visualization of the appendix presenting with the previ-
ously stated radiological criteria of AA and the absence
of any of following CT scan findings resulting in the
diagnosis of complicated AA:
▪ Periappendiceal abscess
▪ Perforated AA (periappendiceal abscess, extraluminal
gas, free peritoneal fluid, focal poor enchancement of
the appendiceal wall)
▪ The presence of appendicolith
▪ Tumour of the appendix
Sample size calculation
The sample size calculation of the trial was based on the
self-evident fact that the efficacy of appendectomy as a
treatment for AA is 100%, but antibiotic therapy will not
provide adequate source control in all patients with un-
complicated AA. However, the hypothesis of the APPAC
trial is that operative treatment of uncomplicated AA is
not mandatory for the majority of patients as 75 – 85%
of patients with uncomplicated AA can be cured with
wide-spectrum antibiotics avoiding a large number of
unnecessary appendectomies [8]. For the primary
endpoint of treatment success for the randomized ther-
apy tested in a randomized, controlled, open label, non-
inferiority multicenter trial, we assumed 99% healing
rate of AA in the appendectomy group vs. 80% success
rate for the antibiotic therapy. A non-inferiority margin
of 24 percentage points was used in the sample size
calculations meaning that the lower limit of the success
in antibiotic therapy would be 75%. We calculated that a
sample size of 275 patients per group would give a
power of 0.9 (1-β) to establish whether antibiotictreatment was not inferior to appendectomy evaluated
by treatment success in both study arms (significance
level of 0.05 α). With an estimated 10 percent of the trial
patients lost to follow-up, a maximum of 610 patients
will be enrolled. For the secondary endpoints data will
be compared as superiority trial setting and in superior-
ity tests a two-tailed P value ≤ 0.05 will be considered
statistically significant. The main analyses will be based
on the intention-to-treat principle, but both intention-to
-treat and per-protocol analyses will be performed.
Cost analysis
All related costs will be estimated based on the actual
input terms of resource use and personnel in the
12-month follow-up period after randomization. All
costs will be derived from the Finnish hospital cost or
determined in co-operation with the hospital administra-
tion. Direct medical costs will be recorded in the case
record forms. Indirect costs arising from losses in pro-
ductivity will be assessed by means of the Health and
Labor questionnaire and will be calculated by means of
the friction cost method.
Safety monitoring
Adverse events are defined as any undesirable experi-
ence occurring to a subject during a clinical trial,
whether or not considered related to the investigational
intervention. All adverse effects reported spontaneously
by the subject or observed by the investigator or the staff
will be recorded. An interim analysis to ensure safety of
the antibiotic treatment will be performed after rando-
mizing 150 – 200 patients.
The radiation exposure caused by abdominal CT is
6 – 8 mSv. One mSv corresponds to four months back-
ground radiation exposure. An abdominal CT scan, with
an estimated effective maximum dose of 10 mSv, raises
the possibility of x-ray induced fatal cancer by 0.05%,
in addition to a base-line life time risk for naturally
induced fatal cancer of 20% in the U.S.. [24]
Ethics and informed consent
This study will be conducted in accordance with the
principles of the Declaration of Helsinki and ‘good cli-
nical practice’ guidelines. The Medical Ethical Commit-
tee of the Turku University Hospital has approved the
protocol and the Ethical Committees of the participating
centers are applied for local feasibility. Prior to CT scan
evaluation and randomization, written informed consent
will be obtained from all patients.
Discussion
The hypothesis of the APPAC trial is that the majority
of patients with uncomplicated AA can be cured with
wide-spectrum antibiotics avoiding a large number of
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supported by previous randomized studies [13-18].
Acute appendicitis is one of the most common urgent
conditions seen in general surgery practice. Although
the exact mechanisms leading to this condition are still
obscure, it is likely that luminal obstruction by external
(lymphoid hyperplasia) or internal (sticked fecal mater-
ial, appendicolith) compression plays a key pathogenetic
role. The luminal obstruction leads to increased mucus
production, bacterial overgrowth, and stasis, which in-
crease appendiceal wall tension. Consequently, blood
and lymph flow is diminished, and necrosis and perfor-
ation follow. As these events occur over time, it is
conceivable that early surgical intervention prevents pro-
gression of disease. However, epidemiologic studies on
incidence of nonperforated and perforated AA suggest
that nonperforated and perforated AA may have differ-
ent pathogenetic mechanisms strongly supporting our
study hypothesis in re-evaluating the dictum that surgi-
cal removal of the appendix is always necessary for
AA [25].
The best design for a therapeutic trial is a randomized
placebo-controlled, double-blind study, but with the
interventions used in the APPAC trial the concealment
would not be possible and therefore a randomized open
design was chosen. As concealment is lacking in all
randomized trials comparing appendectomy with anti-
biotic therapy, the main focus should be on the safety of
antibiotic treatment and the reduction in surgically-
related morbidity and cost savings by using antibiotic
therapy. Our power analysis and study hypothesis are
based on the self-evident fact that efficacy of surgical
treatment will be clinically superior to antibiotic therapy
for uncomplicated AA – no appendix, no appendicitis –
and therefore the primary end-point is treatment efficacy
in both study arms. The primary endpoint of 30-day
post-intervention peritonitis in the study of Vons et al.
[17] is not clearly defined and, in addition, the definition
varies between treatment arms. In the study by Hansson
et al. [14] nearly half of the patients randomized to anti-
biotic group crossed over to the appendectomy group
prior to receiving any drug and were classified as anti-
biotic treatment failures. Regarding these study designs,
particular attention should be made to identify a clear
and concise definition of efficacy to be used for both the
conservative and surgical treatments, standardizing the
different treatment procedures as much as possible [6-8]
even though there is an intrinsic difficulty in defining a
common outcome for both treatment arms.
Before enrolling patients into a randomized trial, the
diagnosis of AA needs to be confirmed by CT, but this
inclusion criterion has been used so far in only one
study [17]. In contrast to this study by Vons et al. [17],
we have determined the presence of intraluminalappendicolith as an important exclusion criterion, as it
has earlier been reported to predict negative outcome of
non-operative management and to predict complicated
AA [26]. Indeed, if Vons et al. had excluded the patients
with an appendicolith from their analysis, no significant
difference in the incidence of post-intervention periton-
itis between the treatment groups would have been
noticed in their study.
The antibiotic therapy has been suboptimal in many
previous randomized studies, as for example in the study
by Vons et al. [17] amoxicillin-clavulanic acid was used
even though this combination has been associated with
considerable Escherichia coli non-susceptibility. Further-
more, the use of this combination may play a role in
both the initial antibiotic treatment failures and the re-
currence of AA considering that this antibiotic treat-
ment is not recommended to be used in the non-
operative treatment of AA [8,22]. The most common
organism in AA is Escherichia coli, and the next most
common is Enterococcus and other Streptococcus species.
Pseudomonas, Klebsiella, and Bacteroides species are
less commonly isolated. Accordingly, the selection of
antibiotics should cover both aerobic and anaerobic bac-
teria [8,22,27]. In the present study ertapenem was chosen
for the antibiotic therapy, because it is is a broad-
spectrum antibiotic with a single-dose daily administration
and the efficacy of ertapenem monotherapy in serious
intra-abdominal infections has been demonstrated [22].
The results of our interim analysis (n = 161)
corresponded both with the hypothesis of our study and
the sample size calculation. Vons et al. [17] reported a
recurrence rate of 26% in the antibiotic group. However,
68% of the patients in their study did not require ap-
pendectomy supporting our study hypothesis, that the
majority of patients (> 70%) with uncomplicated AA can
be treated successfully with antibiotics and unnecessary
appendectomies can be avoided resulting in reduced
morbidity and mortality of surgical treatment of
AA, enormous cost savings and allocation of surgical
resources to other emergency operations. Since so far
only a small number of RCTs (< 1000 patients) with
somewhat impaired methodological quality are available,
more well-designed RCTs are urgently needed to both
conclusively define the role of antibiotic therapy in the
management of uncomplicated AA and to assess the
predictive markers for successful non-operative treat-
ment of uncomplicated AA.Conclusion
The APPAC trial is a randomized controlled open-label
multicenter study comparing emergency appendectomy
with antibiotic therapy (intravenous ertapenem) in the
treatment of uncomplicated acute appendicitis.
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